The National Alliance of Advocates
for Buprenorphine Treatment

Buprenorphine (Suboxone®, Subutex®3, Zubsolv®4, Bunavail™5, Probuphine®6) is an opioid medication used to treat opioid addiction in the privacy of a physician's office.1 Buprenorphine can be dispensed for take-home use, by prescription.1 This, in addition to the pharmacological and safety profile of buprenorphine, makes it an attractive treatment for patients addicted to opioids.2

How the matching system works:




1) After receiving a new patient alert email, physicians log in, the number of patients seeking treatment in range of the practice location will be displayed. Click "view patients".



2) Select patients that best fit your expertise and experience, by clicking on the "email" button.



3) That will bring you to the last step, to send the email to the patient. Patients receive your email instructing them to call your office to further discuss the possibility of treatment. It is then up to the patient to contact you by phone. You may add to or change the outgoing message. Your email address is not given to the patient, or anyone else. Patients cannot email you through the matching system.



Go to Patient Matching System now to log in and try it ......or,

Get More help:


Instruction sheet (2 pages PDF)

 

How do I add an office location if I have more than one?

Other frequently asked questions FAQs

NOTE: Until more patients become aware of this program, some of you will find "0" patients within range of your practice. As the system becomes more popular this should change. If you selected "receive alert emails" when you registered, you will receive an email alert when a new patient in range of your practice registers. This option can be turned off when traffic increases.

Alert emails, how they work

Buprenorphine related literature

Terms: The intent of this site is to efficiently connect patients in need of treatment for opioid dependence with an Office-based Treatment Provider, certified to prescribe buprenorphine. It is in violation of the terms to use this site to solicit for anything other than stated above. Example: it is inconsistent with the terms to use this site to solicit for “Rapid detox”, “inpatient rehab”, or any other treatment that is not considered Office-based Opioid Dependence Treatment with buprenorphine. If you do not have an “X” number from the DEA you are not authorized to use this patient database. See terms of use for more information.

 

If you are having problems please contact us at MakeContact@naabt.org for assistance


This page was last modified on : 03/27/2014

The Purpose of Buprenorphine Treatment:

To suppress the debilitating symptoms of cravings and withdrawal, enabling the patient to engage in therapy, counseling and support, so they can implement positive long-term changes in their lives which develops into the new healthy patterns of behavior necessary to achieve sustained addiction remission. - explain -

The National Alliance of Advocates for Buprenorphine Treatment is a non-profit organization charged with the mission to:

  1. U.S. Food and Drug Administration, FDA Talk Paper, T0238, October 8, 2002, Subutex and Suboxone approved to treat opiate dependence.
  2. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, Md: Substance Abuse and Mental Health Services Administration, 2004.
  3. Subutex Discontinued in the US market in late 2011.
  4. Zubsolv (bup/nx sublingual tablet) FDA approved 7/3/2013 see buprenorphine pipeline graphic -in pharmacies now.
  5. Bunavail (bup/nx bucal film) FDA approved 6/6/2014 see buprenorphine pipeline graphic -in pharmacies now.
  6. Probuphine FDA approved 5/26/2016 - FDA Probuphine press release